Milestone Capex To Revenue from 2010 to 2024
| MIST Stock | USD 1.80 0.06 3.23% |
Capex To Revenue | First Reported 2010-12-31 | Previous Quarter 0.112 | Current Value 0.0666 | Quarterly Volatility 0.01498046 |
Check Milestone Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Milestone Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 1.2 M or Interest Income of 3.7 M, as well as many indicators such as Price To Sales Ratio of 75.32, Dividend Yield of 0.0 or PTB Ratio of 4.49. Milestone financial statements analysis is a perfect complement when working with Milestone Pharmaceuticals Valuation or Volatility modules.
Milestone | Capex To Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.